Cargando…

Rapid and sustained response to immune checkpoint inhibition in cutaneous squamous cell carcinoma after allogenic hematopoietic cell transplant for sézary syndrome

BACKGROUND: Cutaneous squamous cell carcinoma (cSCC) is not uncommon in association with indolent malignancies that were treated with prior radiotherapy and after allogenic bone marrow transplantation. On the other hand, cutaneous T-cell lymphoma (CTCL) is a subtype of non-Hodgkin’s lymphoma which i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khaddour, Karam, Musiek, Amy, Cornelius, Lynn A., Dehdashti, Farrokh, Westervelt, Peter, Fields, Ryan, Ansstas, George
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6894240/ https://www.ncbi.nlm.nih.gov/pubmed/31801591 http://dx.doi.org/10.1186/s40425-019-0801-z

Ejemplares similares

Induced Remission of Metastatic Squamous Cell Carcinoma with an Immune Checkpoint Inhibitor in a Patient with Recessive Dystrophic Epidermolysis Bullosa
por: Khaddour, Karam, et al.
Publicado: (2020)

Metachronous cutaneous squamous cell carcinoma in a young patient as the only presenting symptom to uncover Lynch syndrome with MLH1 Germline mutation
por: Khaddour, Karam, et al.
Publicado: (2020)

ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR MYCOSIS FUNGOIDES AND SEZARY SYNDROME
por: Lechowicz, Mary Jo, et al.
Publicado: (2014)

BRAF-MEK inhibitors as steroid-sparing bridge prior to checkpoint blockade therapy in symptomatic intracranial melanoma
por: Khaddour, Karam, et al.
Publicado: (2021)

Case Report: Stereotactic body radiation treatment for immunotherapy escaped oligometastatic progression in cutaneous melanoma and merkel cell carcinoma
por: Khaddour, Karam, et al.
Publicado: (2023)

Clinical outcomes and longitudinal circulating tumor DNA changes after treatment with nivolumab and olaparib in immunotherapy relapsed melanoma with detected homologous recombination deficiency
por: Khaddour, Karam, et al.
Publicado: (2021)

The Landscape of Novel Therapeutics and Challenges in Glioblastoma Multiforme: Contemporary State and Future Directions
por: Khaddour, Karam, et al.
Publicado: (2020)

Haploidentical Hematopoietic Cell Transplantation Using Posttransplant Cyclophosphamide for Sézary Syndrome
por: Kanda-Kato, Madoka, et al.
Publicado: (2020)

Successful administration of sequential TVEC and pembrolizumab followed by Temozolomide in immunotherapy refractory intracranial metastatic melanoma with acquired B2M mutation
por: Khaddour, Karam, et al.
Publicado: (2020)

Addendum: Successful administration of sequential TVEC and pembrolizumab followed by Temozolomide in immunotherapy refractory intracranial metastatic melanoma with acquired B2M mutation
por: Khaddour, Karam, et al.
Publicado: (2023)

Allogeneic Hematopoietic Stem Cell Transplantation in Cutaneous T-Cell Lymphomas
por: Dumont, Maëlle, et al.
Publicado: (2020)

Normalization of electroretinogram and symptom resolution of melanoma-associated retinopathy with negative autoantibodies after treatment with programmed death-1 (PD-1) inhibitors for metastatic melanoma
por: Khaddour, Karam, et al.
Publicado: (2021)

Cutaneous Legionella infections in allogeneic hematopoietic cell transplantation recipients
por: Vaidya, Toral, et al.
Publicado: (2020)

Allogeneic hematopoietic stem cell transplantation for primary cutaneous T cell lymphomas
por: Paralkar, Vikram R., et al.
Publicado: (2011)

Sézary syndrome originates from heavily mutated hematopoietic progenitors
por: Harro, Carly M., et al.
Publicado: (2023)

The Role of Immune Checkpoint Molecules for Relapse After Allogeneic Hematopoietic Cell Transplantation
por: Köhler, Natalie, et al.
Publicado: (2021)

Cost–utility analysis of mogamulizumab in advanced mycosis fungoides and Sézary syndrome cutaneous T-cell lymphoma
por: Muszbek, Noemi, et al.
Publicado: (2023)

Melanoma Targeted Therapies beyond BRAF-Mutant Melanoma: Potential Druggable Mutations and Novel Treatment Approaches
por: Khaddour, Karam, et al.
Publicado: (2021)

Case report: Real-world experience using a personalized cancer-specific circulating tumor DNA assay in different metastatic melanoma scenarios
por: Khaddour, Karam, et al.
Publicado: (2022)

Measurement of Quality of Life in Patients with Mycosis Fungoides/Sézary Syndrome Cutaneous T-Cell Lymphoma: Development of an Electronic Instrument
por: McCaffrey, Stacey, et al.
Publicado: (2019)

Microenvironment-dependent growth of Sezary cells in humanized IL-15 mice
por: Gao, Jie, et al.
Publicado: (2023)

Alemtuzumab in refractory Sézary syndrome
por: Reifs, Carmen María Alcántara, et al.
Publicado: (2016)

Plantar keratoderma of Sézary syndrome
por: Fragkos, Konstantinos C.
Publicado: (2017)

Mycosis fungoides and Sézary syndrome
por: Jonak, Constanze, et al.
Publicado: (2021)

Mycosis fungoides and Sézary syndrome
por: Lee, Hyewon
Publicado: (2023)

Dupilumab-Associated Sezary Syndrome
por: Hamp, Austin, et al.
Publicado: (2023)

Structural variation of centromeric endogenous retroviruses in human populations and their impact on cutaneous T-cell lymphoma, Sézary syndrome, and HIV infection
por: Kaplan, Mark H., et al.
Publicado: (2019)

Dermoscopy of Cutaneous Graft-Versus-Host-Disease in Patients After Allogeneic Hematopoietic Stem Cell Transplantation
por: Kaminska-Winciorek, Grażyna, et al.
Publicado: (2020)

Benefit/risk Ratio of Low-dose Methotrexate in Cutaneous Lesions of Mycosis Fungoides and Sézary Syndrome
por: ALENEZI, Fawaz, et al.
Publicado: (2021)

Obesity, Sarcopenia, and Outcomes in Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors
por: Khaddour, Karam, et al.
Publicado: (2020)

Hematopoietic stem cell mobilization for allogeneic stem cell transplantation by motixafortide, a novel CXCR4 inhibitor
por: Crees, Zachary D., et al.
Publicado: (2023)

Sustained remission of recalcitrant cutaneous lymphoid hyperplasia after thalidomide treatment
por: Erickson, Stephen P., et al.
Publicado: (2018)

Long-term complete remission of early hematological relapse after discontinuation of immunosuppressants following allogeneic transplantation for Sezary syndrome
por: Hosoi, Hiroki, et al.
Publicado: (2018)

Cytotoxic Pathways in Allogeneic Hematopoietic Cell Transplantation
por: Du, Wei, et al.
Publicado: (2018)

Allogeneic hematopoietic stem-cell transplantation for myelofibrosis
por: Zhang, Lining, et al.
Publicado: (2020)

Allogeneic Hematopoietic Cell Transplantation and Cellular Therapy
por: Kim, Hee-Je, et al.
Publicado: (2021)

Integrated Genomic Analysis of Sézary Syndrome
por: Mao, Xin, et al.
Publicado: (2011)

A mouse model for the Sézary syndrome
por: Doebbeling, Udo
Publicado: (2010)

Gene Expression Comparison between Sézary Syndrome and Lymphocytic-Variant Hypereosinophilic Syndrome Refines Biomarkers for Sézary Syndrome
por: Moerman-Herzog, Andrea, et al.
Publicado: (2020)

Targeting the CD27-CD70 Pathway to Improve Outcomes in Both Checkpoint Immunotherapy and Allogeneic Hematopoietic Cell Transplantation
por: Lutfi, Forat, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cke8gk1b1i3d9els9vki23vs7e